Tenderwize
Retour à la recherche

Open-house rebate agreement for Tiaprid

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Dec 03, 2027 · 461 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Tiaprid, ATC N05AL03

62/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

62 / 100

Complexité

58 / 100

Facteurs de risque

The notice explicitly says the contract documents must be submitted via the communication area in the DTVP portal and n...

Only pharmaceutical companies are eligible as potential contract partners, and a signed declaration of reliability is r...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jan 2028
  • Non-exclusive open-house rebate agreements for the medicinal product Tiaprid, ATC N05AL03.
  • Supply contract for pharmaceutical products.
Afficher le résumé complet

This is an open-house pharmaceutical supply arrangement for Tiaprid (ATC N05AL03) led by AOK Bayern. It is not a competitive open procedure in substance: the notice states that all interested pharmaceutical companies meeting the stated suitability requirement may join on identical, non-negotiable terms. The contract period runs from 2026-02-01 to 2028-01-31, with contract entry possible until 2027-12-03. Submission is via DTVP electronic channel with a qualified electronic signature, or by signed paper originals in duplicate. No contract value is stated.

Risques

The notice explicitly says the contract documents must be submitted via the communication area in the DTVP portal and n...

Only pharmaceutical companies are eligible as potential contract partners, and a signed declaration of reliability is r...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • Submit the signed contract, the completed annex 'Festlegung der vertragsgegenständlichen Arzneimittel', and the signed declaration of reliability.
  • The declaration of reliability must be signed and submitted with the tender documents.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open-house rebate agreement for Tiaprid

Open-house non-exclusive pharmaceutical rebate agreement for Tiaprid (ATC N05AL03). Scope is supply of pharmaceutical products under a pre-set contract; the notice says the contract terms are identical and not individually negotiable. Place of performance is Germany, region DE212 (Bavaria/Munich area as indicated by buyer address and lot data).

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Jan 2026 - Jan 2028

Catégorie

Pharmaceutical products

Date limite

Deadline Dec 03, 2027

Détails de la procédure

Date de publication
14 Dec 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
831717-2025

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30